HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity
Cell · 2025-03 · 188 (6) · 1580-1588.e11
DOI: 10.1016/j.cell.2025.01.029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2025-03. Verfasst von Skyler Y Blume und 16 weiteren Autor:innen. Beteiligte Einrichtung: Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco…. Hauptthemen laut MEDLINE: Oxygen, Hypoxia, Hemoglobins, Leigh Disease. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
We have previously demonstrated that chronic inhaled hypoxia is remarkably therapeutic in the premier animal model of mitochondrial Leigh syndrome, the Ndufs4 knockout (KO) mouse. Subsequent work has extended this finding to additional mitochondrial diseases and more common conditions. However, challenges inherent to gas-based therapies have hindered the rapid translation of our findings to the clinic. Here, we tested a small molecule (hereafter termed HypoxyStat) that increases the binding affinity of hemoglobin for oxygen, thereby decreasing oxygen offloading to tissues. Daily oral dosing of HypoxyStat caused systemic hypoxia in mice breathing normoxic (21% O2) air. When administered prior to disease onset, this treatment dramatically extended the lifespan of Ndufs4 KO mice and rescued additional aspects of disease, including behavior, body weight, neuropathology, and body temperature. HypoxyStat was also able to reverse disease at a very late stage, thereby serving as a clinically tractable form of hypoxia therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA.
- Maze Therapeutics, 171 Oyster Point Blvd STE 300, South San Francisco, CA 94080, USA.
- Gladstone Institutes, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94158, USA; Arc Institute, 3181 Porter Dr, Palo Alto, CA 94304, U…
Förderung
- NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- Maze Therapeutics Inc
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of General Medical Sciences
- US Office of Congressionally Directed Medical Research Programs
Zitieren
APA
Blume, S. Y., Garg, A., Martí-Mateos, Y., Midha, A. D., Chew, B. T. L., Lin, B., Yu, C., Dick, R., Lee, P. S., Situ, E., Sarwaikar, R., Green, E., Ramanan, V., Grotenbreg, G., Hoek, M., Sinz, C., & Jain, I. H. (2025). HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity. Cell, 188(6), 1580-1588.e11. https://doi.org/10.1016/j.cell.2025.01.029
Vancouver
Blume SY, Garg A, Martí-Mateos Y, Midha AD, Chew BTL, Lin B, et al. HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity. Cell. 2025;188(6):1580-1588.e11. doi:10.1016/j.cell.2025.01.029
BibTeX
@article{Blume2025,
author = {Blume, Skyler Y and Garg, Ankur and Martí-Mateos, Yolanda and Midha, Ayush D and Chew, Brandon T L and Lin, Baiwei and Yu, Cecile and Dick, Ryan and Lee, Patrick S and Situ, Eva and Sarwaikar, Richa and Green, Eric and Ramanan, Vyas and Grotenbreg, Gijsbert and Hoek, Maarten and Sinz, Christopher and Jain, Isha H},
title = {HypoxyStat, a small-molecule form of hypoxia therapy that increases oxygen-hemoglobin affinity},
journal = {Cell},
year = {2025},
volume = {188},
number = {6},
pages = {1580--1588.e11},
doi = {10.1016/j.cell.2025.01.029}
}
EUVIMED